查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813939

肝纖維化生物標記市場規模、佔有率和趨勢分析報告：按產品、技術、最終用途、地區和細分市場預測，2025-2033 年

Hepatic Fibrosis Biomarkers Market Size, Share & Trends Analysis Report By Product (Blood-based Kits, Saliva-based Kits), By Technology (Immunofiltration Assays, Lateral Flow Assays), By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

肝纖維化生物標記市場摘要

2024 年全球肝纖維化生物標記市場價值估計為 4.2351 億美元，預計到 2033 年將達到 22.9173 億美元，2025 年至 2033 年的複合年成長率為 20.01%。

由於肥胖、久坐的生活方式和METABOLIC INC.症候群導致 NASH 盛行率不斷上升，人們對肝纖維化生物標記的興趣日益濃厚。

根據美國國立糖尿病、消化和腎臟疾病研究所發表的一項研究，NAFLD 影響三分之一至三分之二的第 2 型糖尿病患者。其他研究也表明，超過 90% 的極度肥胖者和高達 75% 的超重者患有 NAFLD。推動 NASH特異性肝纖維化生物標記需求的主要因素之一是纖維化分期的臨床意義。鑑於肝臟切片檢查的風險和局限性，非侵入性生物標記為監測 NASH 患者的肝纖維化進展提供了一種更安全、更方便患者的治療方法。

最新估計顯示，全球約有3.3%的人口患有晚期肝纖維化，而使用振動控制瞬時彈性成像(VCTE)測量時，這一比例將上升至約3.5%。非酒精性脂肪肝病(NAFLD)，最近被重新定義為代謝功能障礙相關脂肪性肝病(MASLD)，影響著全球約25%的人口，由於肥胖和2型糖尿病發病率的上升，預計2016年至2019年期間某些地區的患病率將升至38%。

ELF、FIB-4、NAFLD 纖維化評分、APRI、FibroTest/FibroSure 等檢測，以及 IGFBP7/SSc5D/Sema4D 等新興多標誌物組合的採用，使得早期檢測、準確分期以及減少對侵入性切片檢查的依賴成為可能。這些進展，加上篩檢力道的不斷增加，使得肝纖維化生物標記成為應對全球肝病流行的核心工具。

肝纖維化的動態變化，特別是NASH等肝病的非侵入性生物標記物，為評估患者病情進展提供了新的工具。此類肝病指標可用於高風險患者臨床試驗中的患者風險分層和預後評估，從而提高成功率。這些循環生物標記還能提供肝纖維化動態變化的精確指標，並可用於衡量指定治療的成敗。 Nordic Bioscience的NASH專家可以檢測一系列精確的肝纖維化生物標記物，包括PRO-C3 NASH生物標記物，以了解疾病的病程。

目錄

第 1 章肝纖維化生物標記市場：調查方法與範圍

2. 肝纖維化生物標記市場：執行摘要

  • 市場概述
  • 產品和技術概覽
  • 最終用途簡介
  • 競爭格局簡介

3. 肝纖維化生物標記市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章肝纖維化生物標記市場：產品評估與趨勢分析

  • 肝纖維化生物標記市場：產品差異分析
  • 套件和試劑
  • 偵測
  • 服務

第5章肝纖維化生物標記市場：技術評估與趨勢分析

  • 肝纖維化生物標記市場：技術波動分析
  • 免疫檢測
  • 分子診斷
  • 蛋白質體學/代謝體學
  • 基於影像的生物標記評估

第6章肝纖維化生物標記市場：最終用途估計和趨勢分析

  • 肝纖維化生物標記市場：最終用途變異分析
  • 醫院
  • 診斷實驗室
  • 專科診所
  • 學術研究機構
  • 製藥和生物技術公司

7. 肝纖維化生物標記市場：區域業務分析

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第8章 競爭態勢

  • 公司分類
  • 戰略地圖
    • 新產品發布
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 2024年主要企業市佔率分析
  • 公司熱圖分析
  • 公司簡介
    • GENFIT
    • Prometheus Laboratories
    • Siemens Healthineers AG
    • BioPredictive
    • Quest Diagnostics
    • AstraZeneca
    • Exalenz Bioscience Ltd（meridian bioscience）
    • Labcorp
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68040-714-2

Hepatic Fibrosis Biomarkers Market Summary

The global hepatic fibrosis biomarkers market size was estimated at USD 423.51 million in 2024 and is projected to reach USD 2,291.73 million by 2033, growing at a CAGR of 20.01% from 2025 to 2033. The rising prevalence of NASH, a consequence of obesity, sedentary lifestyles, and metabolic syndrome, has led to a greater focus on hepatic fibrosis biomarkers.

According to the study published in the National Institutes of Diabetes and Digestive and Kidney Diseases, NAFLD affects one-third to two-thirds of individuals with type 2 diabetes. Studies also indicate that over 90% of individuals with extreme obesity and up to 75% of overweight individuals have NAFLD. One of the key drivers propelling the demand for NASH-specific hepatic fibrosis biomarkers is the clinical significance of fibrosis staging. The risks and limitations associated with liver biopsies and non-invasive biomarkers offer a safer and more patient-friendly approach to monitoring hepatic fibrosis progression in NASH patients.

As of the most recent estimates, approximately 3.3% of the global population is living with advanced hepatic fibrosis, with rates rising to around 3.5% when measured using vibration-controlled transient elastography (VCTE). Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD), affects about 25% of the world's population, with prevalence increasing to 38% in certain regions between 2016 and 2019 due to rising obesity and type 2 diabetes rates.

The adoption of tests such as ELF, FIB-4, NAFLD fibrosis score, APRI, and FibroTest/FibroSure, alongside emerging multi-marker panels like IGFBP7/SSc5D/Sema4D, is enabling earlier detection, accurate staging, and reduced reliance on invasive liver biopsies. These advancements, combined with rising screening initiatives, are positioning hepatic fibrosis biomarkers as a central tool in tackling the global liver disease epidemic.

The dynamics of liver fibrosis are specifically targeted by noninvasive biomarkers of liver condition, such as NASH, which offer a novel tool to assess a patient's disease progression. Such indicators for liver illness could be applied to patient risk classification as well as prognostic enrichment of clinical trials aimed at the individuals with the highest risk, improving the likelihood of success. These blood biomarkers are also accurate indicators of the dynamics of liver fibrosis and can be used to gauge the success of a given treatment. Nordic Bioscience NASH specialists can examine a precise panel of liver fibrosis biomarkers, including the biomarker PRO-C3 NASH, which offers insight into the course of the illness.

Global Hepatic Fibrosis Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hepatic fibrosis biomarkers market report based on product, technology, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Kits and Reagents
  • Assays
  • Services
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Immunoassay
  • Molecular Diagnostics
  • Proteomics/Metabolomics
  • Imaging-based Biomarker Assessment
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Specialty Clinics
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Hepatic Fibrosis Biomarkers Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Technology Segment
      • 1.1.1.3. Sample Product segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Hepatic Fibrosis Biomarkers Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Technology Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Hepatic Fibrosis Biomarkers Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
  • 3.5. Market Restraint Analysis
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Hepatic Fibrosis Biomarkers Market: Product Estimates & Trend Analysis

  • 4.1. Hepatic Fibrosis Biomarkers Market: Product Movement Analysis
  • 4.2. Kits and Reagents
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Assays
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Services
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Hepatic Fibrosis Biomarkers Market: Technology Estimates & Trend Analysis

  • 5.1. Hepatic Fibrosis Biomarkers Market: Technology Movement Analysis
  • 5.2. Immunoassays
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Molecular Diagnostics
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Proteomics/Metabolomics
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Imaging-based Biomarker Assessment
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Hepatic Fibrosis Biomarkers Market: End Use Estimates & Trend Analysis

  • 6.1. Hepatic Fibrosis Biomarkers Market: End Use Movement Analysis
  • 6.2. Hospitals
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Diagnostics Laboratories
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Specialty Clinics
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Academic & Research Institutes
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Pharmaceutical & Biotechnology Companies
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Hepatic Fibrosis Biomarkers Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Hepatic Fibrosis Biomarkers Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Hepatic Fibrosis Biomarkers Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Product Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. GENFIT
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Prometheus Laboratories
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Siemens Healthineers AG
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. BioPredictive
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Quest Diagnostics
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AstraZeneca
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Exalenz Bioscience Ltd (meridian bioscience)
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Labcorp
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Pfizer Inc.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Bristol-Myers Squibb Company
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Hepatic Fibrosis Biomarkers Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 5 Global Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 6 Global Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Hepatic Fibrosis Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 9 North America Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 10 North America Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 12 U.S. Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 13 U.S. Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 15 Canada Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 Canada Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 18 Mexico Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 19 Mexico Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Hepatic Fibrosis Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 22 Europe Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 23 Europe Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 25 UK Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 26 UK Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 28 Germany Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Germany Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 31 France Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 32 France Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 34 Italy Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 35 Italy Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 37 Spain Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 38 Spain Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 40 Sweden Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 Sweden Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 43 Norway Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 44 Norway Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 46 Denmark Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 47 Denmark Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Hepatic Fibrosis Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 53 Japan Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 54 Japan Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 56 China Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 China Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 59 India Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 60 India Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 62 Australia Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 63 Australia Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 65 Thailand Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Thailand Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 68 South Korea Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 69 South Korea Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Hepatic Fibrosis Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 72 Latin America Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 73 Latin America Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 75 Brazil Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 76 Brazil Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 78 Argentina Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 79 Argentina Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Hepatic Fibrosis Biomarkers Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 82 MEA Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 83 MEA Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 85 South Africa Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 South Africa Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 91 UAE Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 92 UAE Hepatic Fibrosis Biomarkers Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Hepatic Fibrosis Biomarkers Market, By Product, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Hepatic Fibrosis Biomarkers Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Hepatic Fibrosis Biomarkers Market, By End Use, 32021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global Hepatic fibrosis biomarkers market- Key market driver analysis
  • Fig. 7 Global Hepatic fibrosis biomarkers market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global Hepatic fibrosis biomarkers market - Porter's analysis
  • Fig. 10 Global Hepatic fibrosis biomarkers market - PESTEL analysis
  • Fig. 11 Global Hepatic fibrosis biomarkers market Product outlook key takeaways
  • Fig. 12 Global Hepatic fibrosis biomarkers market: Product movement analysis
  • Fig. 13 Kits and reagents market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Reagents market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Services market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Global Hepatic fibrosis biomarkers market technology outlook key takeaways
  • Fig. 17 Global Hepatic fibrosis biomarkers market: technology movement analysis
  • Fig. 18 Immunoassays market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Molecular diagnostics market estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Proteomics/metabolomics market estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Imaging-based biomarker assessment market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Global Hepatic fibrosis biomarkers market end use outlook key takeaways
  • Fig. 23 Global Hepatic fibrosis biomarkers market: end use movement analysis
  • Fig. 24 Retail and online pharmacies market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Hospitals and diagnostics laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 26 NGO/Community-based distribution market estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Global Hepatic Fibrosis Biomarkers market: Regional movement analysis
  • Fig. 29 North America Hepatic Fibrosis Biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 31 Canada Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 32 Mexico Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 34 UK Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 35 Germany Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 36 France Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 37 Spain Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 38 Italy Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 39 Denmark Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 40 Sweden Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 41 Norway Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 42 Asia Pacific Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 43 Japan Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 44 China Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 45 India Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 46 South Korea Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 47 Australia Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 48 Thailand Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 49 Latin America Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 50 Brazil Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 51 Argentina Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 52 MEA Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 53 South Africa Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 54 Saudi Arabia Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 55 UAE Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 56 Kuwait Hepatic fibrosis biomarkers market, 2021 - 2033 (USD Million)
  • Fig. 57 Strategy framework